Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery

This study has been completed.
Sponsor:
Collaborator:
Vanderbilt University
Information provided by (Responsible Party):
Asklepion Pharmaceuticals, LLC
ClinicalTrials.gov Identifier:
NCT00335244
First received: June 7, 2006
Last updated: May 21, 2013
Last verified: May 2013

June 7, 2006
May 21, 2013
May 2006
December 2009   (final data collection date for primary outcome measure)
Duration of postoperative mechanical ventilation in hours compared between treatment groups. [ Time Frame: Measured in hours from the end of surgery until extubation ] [ Designated as safety issue: Yes ]
Increased PVT will be defined as a sustained mean pulmonary artery pressure > 20 mmHg for at least 2 hours during the first 48 hours postoperatively.
Complete list of historical versions of study NCT00335244 on ClinicalTrials.gov Archive Site
  • Incidence of increased PVT (defined as a sustained mean pulmonary artery pressure greater than 20 mm Hg for at least 2 hours, measured during the first 48 hours [ Time Frame: Measured in hours from the end of surgery until extubation ] [ Designated as safety issue: Yes ]
  • Postoperative intravenous inotrope score [ Time Frame: Measured at 48 hours ] [ Designated as safety issue: No ]
  • Length and volume of chest tube drainage [ Time Frame: Measured in hours from the end of surgery until removal of chest tubes ] [ Designated as safety issue: No ]
  • Length of ICU stay [ Time Frame: Measured in hours from the end of surgery to discharge from ICU ] [ Designated as safety issue: No ]
  • Length of hospitalization [ Time Frame: Measured from the day of surgery until discharge from hospital ] [ Designated as safety issue: No ]
  • Survival [ Time Frame: Measured at 30 days post surgical repair ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery
A Phase III Double Blind, Randomized, Placebo Controlled, Clinical Trial to Determine the Safety and Efficacy of Intravenous L-Citrulline Versus Placebo in Children Undergoing Cardiopulmonary Bypass

This clinical trial will determine the safety and effectiveness of intravenous L-citrulline in children undergoing cardiopulmonary bypass during heart surgery. Participants will be randomly assigned to either L-citrulline or a placebo (a substance that has no medicine in it).

Citrulline is a protein building block in the body that can convert into another substance, nitric oxide (NO), which controls blood pressure in the lungs. Increased blood pressure in the lungs can be an important surgical problem; it may also lead to problems following surgery, such as severe high blood pressure in the lungs (pulmonary hypertension), increased time spent on a breathing machine, and a longer stay in the intensive care unit (ICU). The hypothesis of this study is that perioperative supplementation with intravenous citrulline will increase plasma citrulline, arginine and NO metabolites and prevent elevations in the postoperative PVT leading to a decrease in the duration of postoperative invasive mechanical ventilation.

Increased pulmonary vascular tone (PVT) can complicate the postoperative course of the following five surgical procedures for congenital heart defects: 1) unrestrictive ventricular septal defect (VSD) repair; 2) atrioventricular septal (AVSD) repair; 3) arterial switch procedure for transposition of the great arteries (TGA); 4) bidirectional Glenn shunt procedure; and 5) Fontan procedure for single ventricle lesions. PVT is partially controlled by NO. Arginine, the precursor to NO, is a product of the urea cycle. Preliminary data have been presented regarding 169 infants and children who have undergone one of six previous surgical procedures. It was found that urea cycle function and plasma arginine levels were significantly decreased in all participants. Furthermore, participants with increased PVT had significantly lower arginine levels compared to participants with normal PVT. Finally, a genetic single nucleotide polymorphism (SNP) in the rate limiting urea cycle enzyme (carbamyl phosphate synthetase I [CPSl T1405N]) appeared to affect postoperative plasma arginine levels and PVT. The hypothesis is that genetic polymorphisms in the rate limiting urea cycle enzyme CPSl, and other important enzymes in the urea cycle, influence the availability of NO precursors. It is further hypothesized that perioperative enhancement of urea cycle function with the key urea cycle intermediate (citrulline) will increase plasma arginine and NO metabolites and prevent elevations in PVT.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Heart Defects, Congenital
  • Hypertension, Pulmonary
  • Drug: L-citrulline
    150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
  • Drug: Placebo of intravenous L-citrulline
    Placebo of intravenous L-citrulline
  • Experimental: 1
    Intravenous L-citrulline
    Intervention: Drug: L-citrulline
  • Placebo Comparator: 2
    Placebo of intravenous L-citrulline
    Intervention: Drug: Placebo of intravenous L-citrulline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
77
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Undergoing cardiopulmonary bypass surgery with 1 of the following 5 procedures:

    1. AVSD repair
    2. VSD repair
    3. Bidirectional Glenn
    4. Modified Fontan
    5. Arterial switch

Exclusion Criteria:

  • Pulmonary artery or vein abnormalities not being addressed surgically
  • Preoperative requirement for mechanical ventilation or intravenous inotrope support
  • Any condition that might interfere with study objectives, as determined by the investigator
  • Pregnant
Both
up to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00335244
409, R01 HL73317-01, IRB# 060197
Yes
Asklepion Pharmaceuticals, LLC
Asklepion Pharmaceuticals, LLC
Vanderbilt University
Principal Investigator: Fredrick E. Barr, MD, MSCI Vanderbilt University
Asklepion Pharmaceuticals, LLC
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP